Genmab
In February 1999, Florian Schönharting, the managing director of the biomedical venture firm BankInvest, established the Danish biotech business Genmab.
Genmab is headquartered in Copenhagen, Denmark, and operates internationally through its subsidiaries Genmab BV in Utrecht, Netherlands, Genmab US, Inc. in Princeton, USA and Genmab KK in Tokyo, Japan. Genmab operates as a dual-listed business, with its shares trading on the NASDAQ Global Select Market in the US and the Copenhagen Stock Exchange in Denmark.
The company has produced six different antibody types (monoclonal and dual specific) which have been authorized for use in six commercial goods, including treatments for autoimmune and cancer conditions. Specifically, Genmab manufactures and distributes exclusively Tivdak (tisotumab vedotin-tftv) for the treatment of previously treated recurrent or metastatic cervical cancer. The remaining 5 antibodies are marketed by partners and include Darzalex, which is used to treat multiple myeloma in all stages, Rybrevant, which is used to treat non-small cell lung cancer, Tecvayli, which is used to treat relapse/ refractory MS, Kesimpta, which is used to treat recurrent MS, and Tepezza, which is used to treat thyroid-related eye disease.
Additionally, a variety of antibody programs based on Genmab technology are being developed by Genmab and its collaborators for the treatment of autoimmune and cancer illnesses. Genmab has obtained a license from the American biopharmaceutical company Medarex to use their HuMab-Mouse technology to produce completely human, high-affinity antibodies in transgenic mice. One advantage of using this kind of technology is that it does not require cloning or intricate genetic engineering to make this antibody suitable for human use, which reduces the cost and duration of its development. It may be created in a matter of months and can be chosen to attach to particular antigens, such as cancer cells and other infectious pathogens. Additionally, these antibodies are less likely to result in allergic responses and other negative effects.
Industry: Biotechnology
Founded: 1999
Headquarters: Copenhagen, Denmark
Website: https://www.genmab.com/
